Pfizer reached a voluntary agreement with the Trump administration on September 30, 2025, to cut prescription drug costs for American patients by matching prices in other developed countries and offering discounts up to 85% via a forthcoming federal platform, TrumpRx.gov, while committing $70 billion to U.S.-based R&D and manufacturing in exchange for a three-year tariff…